Research – Dyadic (DYAI) – SEC filing on track

Posted on by Admin

Wednesday, February 20, 2019

Dyadic International Inc. (DYAI)

SEC filing on track; pursuit towards Nasdaq Up-listing.

Dyadic International
Inc. is a biotechnology company developing a proprietary expression platform to
manufacture of biologic products. The company is employing C1 technology, part
of a fungi expression system, to produce variety of modalities of biologic
products, including vaccines, oncolytic viruses, monoclonal and bispecific
antibodies, as well as biosimilars.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

RATING: OUTPERFORM

  • Now an SEC Filing company. Dyadic International announced the effectiveness of Form 10, filed with the Securities and Exchange Commission (SEC) on February 12, 2019. 
  • Nasdaq Uplisting. The company is pursuing to have its common stock listed on the NASDAQ Capital Markets Exchange. The SEC filing is a positive accomplishment moving towards the uplisting. Dyadic is required to maintain a mini…


    GO TO FULL REPORT



    Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Leave a Reply